MedPath

Is Serum YKL-40 Capable of Predicting Intrauterine Growth Restriction (IUGR) and Preeclampsia?

Conditions
Intrauterine Growth Restriction
Preeclampsia
Interventions
Procedure: ultrasound
Registration Number
NCT00836524
Lead Sponsor
Zealand University Hospital
Brief Summary

Objective: To investigate the role of maternal serum YKL-40 and uterine artery doppler, at gestational age 12, 20, 25 and 32 weeks, and the relation to preeclampsia and intrauterine growth restriction. The serum marker YKL-40 is related to conditions involving inflammation, infection, tissue remodeling, fibrosis and cancer. IUGR and preeclampsia are known to be related to inflammation and tissue remodeling.

Methods: women attending screening for downs syndrome is scanned with uterine artery doppler and delivered blood samples at GA 12, 20, 25 and 32 respectively. When pregnancy outcome is registered by medical records blood samples are retrieved and analyzed for serum YKL-40. Serum YKL-40 are correlated to the presence of bilateral notching, preeclampsia and different degrees of intrauterine growth restriction.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
2000
Inclusion Criteria
  • Pregnant danish speeking women
Exclusion Criteria
  • Conditions/diseases involving chronical inflammation, or immunological activity

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
1ultrasoundPregnant women are included when they attend nuchal transcluency examination and will during their pregnancy be examined 4 times with ultrasound
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Gynækologisk-Obstetrisk Afdeling, Sygehus Nord

🇩🇰

Roskilde, Region Sjælland, Denmark

© Copyright 2025. All Rights Reserved by MedPath